[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100473585":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":32,"centralContacts":36,"locations":45,"responsibleParty":64,"collaborators":10,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":10,"enrollmentInfo":76,"targetDuration":10,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":10,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Washington University School of Medicine","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"depression",null,"All participants will receive two one time PET scans with tracers AV1451 and PIB to detect tau and amyloid in the brain.",[13,14],"Drug: F 18 AV-1451 (Flortaucipir)","Drug: [11C]-Pittsburgh Compound B ([11C]PiB)",{"label":16,"type":10,"description":11,"interventionNames":17},"control",[13,14],[19,26],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","F 18 AV-1451 (Flortaucipir)","A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for \\[18F\\] AV-1451. A PET-certified medical professional will prepare and administer the \\[18F\\] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of \\[18F\\] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).",[16,9],[25],"AV-1451",{"type":20,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"[11C]-Pittsburgh Compound B ([11C]PiB)","A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for \\[11C\\] PIB. A PET-certified medical professional will prepare and administer the \\[11C\\] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of \\[11C\\] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.",[16,9],[31],"PIB",[33],{"name":34,"affiliation":5,"role":35},"Beau Ances, MD, PhD","PRINCIPAL_INVESTIGATOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":10,"email":41},"Kaylin Taylor, MA","CONTACT","314-273-3573","kaylin.james@wustl.edu",{"name":34,"role":39,"phone":43,"phoneExt":10,"email":44},"(314) 747-8423","bances@wustl.edu",[46],{"facility":5,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"RECRUITING","St Louis","Missouri","63110","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-90.19789,38.62727,{"lat":57,"lon":56},[60,62],{"name":38,"role":39,"phone":40,"phoneExt":10,"email":61},"msamantha@wustl.edu",{"name":34,"role":39,"phone":63,"phoneExt":10,"email":44},"(314)747-8423",{"type":65,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100473585","depression-and-driving-100473585",false,"NCT05446805","Depression and Driving","The Impact of Depression and Preclinical Alzheimer Disease on Driving Among Older Adults (Depression and Driving)","D&D","Inclusion Criteria:\n\n* Drive on average at least once per week\n* Has a valid driver's license\n* Willing to complete blood draw\n* Willing to complete either lumbar puncture or PET imaging\n* 65 years or older\n* Speaks English\n\nExclusion Criteria:\n\n* Not willing to complete blood draw and\u002For one other biomarker\n* Less than 65 years of age\n* Does not drive a vehicle\u002F is no longer actively driving","ALL","65 Years",{"count":77,"type":78},150,"ESTIMATED","OBSERVATIONAL","This project will assess how depression, preclinical AD, and antidepressants affect driving behavior in cognitively normal older adults (65 years).",[82,83],"Depression","Drive","2026-06-04",{"date":86,"type":87},"2026-06-08","ACTUAL",{"date":89,"type":87},"2021-06-17",{"date":91,"type":78},"2027-12-17",{"name":5,"class":6},1]